NanoVibronix Inc ( NAOV ) shares are trading higher by 37.4% to $3.03 during Monday’s session after the company announced Friday that it published its UroShield study, which showed positive data, including an 86% UTI reduction.

What To Know: NanoVibronix ( NAOV ) announced that a study on its UroShield device, published in The Australian and New Zealand Continence Journal, confirms its effectiveness in preventing catheter-associated urinary tract infections.

The study found that UroShield reduced UTIs by 86%, catheter blockages by 70%, and bladder irrigations by 82.8%, while also improving patient comfort and reducing catheter changes. Clinicians reported lower intervention needs and nursing time, leading to measurable cost savings.

What Else: A Quality Improvement project in New Zealand demonstrated a 63.5% reduction in resource costs over five months, highlighting UroShield's potential to enhance patient care and reduce healthcare expenses.

CEO Brian Murphy emphasized its role in improving quality of life and easing nursing workloads, reinforcing its suitability for broader adoption in healthcare settings.

Read Also: Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains

How To Buy NAOV Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in NanoVibronix’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, NAOV has a 52-week high of $13.97 and a 52-week low of $1.02.